DNB Asset Management AS increased its stake in West Pharmaceutical Services, Inc. (New York Stock Exchange: WST – Get a rating) by 10.8% in Q1, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 14,499 shares of the medical device supplier after acquiring an additional 1,417 shares during the period. DNB Asset Management AS’s holdings in West Pharmaceutical Services were worth $5,955,000 when it last filed with the Securities & Exchange Commission.
Other large investors also bought and sold shares of the company. Moors & Cabot Inc. acquired a new position in shares of West Pharmaceutical Services during the third quarter worth $36,000. Northwest Investment Counselors LLC acquired a new position in shares of West Pharmaceutical Services during the fourth quarter at a value of $47,000. Dividend Assets Capital LLC acquired a new position in shares of West Pharmaceutical Services during the fourth quarter at a value of $51,000. Sageworth Trust Co of South Dakota acquired a new position in shares of West Pharmaceutical Services during the fourth quarter worth $56,000. Finally, Confluence Wealth Services Inc. acquired a new position in West Pharmaceutical Services in the fourth quarter worth $67,000. Institutional investors and hedge funds own 93.25% of the company’s shares.
NYSE WST opened at $288.83 on Thursday. The company has a debt ratio of 0.09, a current ratio of 2.89 and a quick ratio of 2.18. West Pharmaceutical Services, Inc. has a 1-year low of $275.89 and a 1-year high of $475.35. The company has a market capitalization of $21.40 billion, a PE ratio of 32.09, a P/E/G ratio of 2.91 and a beta of 1.18. The company has a fifty-day moving average of $314.16 and a two-hundred-day moving average of $373.23.
Western Pharmaceutical Services (New York Stock Exchange: WST – Get a rating) last released its quarterly earnings data on Thursday, April 28. The medical device supplier reported earnings per share (EPS) of $2.30 for the quarter, beating the consensus estimate of $2.18 by $0.12. West Pharmaceutical Services achieved a net margin of 23.76% and a return on equity of 30.33%. The company had revenue of $720.00 million in the quarter, versus a consensus estimate of $720.92 million. In the same quarter a year earlier, the company posted earnings of $2.05 per share. West Pharmaceutical Services revenue for the quarter increased 7.4% year-over-year. On average, research analysts expect West Pharmaceutical Services, Inc. to post earnings per share of 9.33 for the current year.
The company also recently announced a quarterly dividend, which will be paid on Wednesday, August 3. Shareholders of record on Wednesday, July 20 will receive a dividend of $0.18. The ex-dividend date is Tuesday, July 19. This represents a dividend of $0.72 on an annualized basis and a dividend yield of 0.25%. West Pharmaceutical Services payout rate is 8.00%.
Separately, StockNews.com downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating in a Thursday, April 28 research note.
Western Pharmacy Services Profile (Get a rating)
West Pharmaceutical Services, Inc. designs, manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, Middle East, Africa and Asia-Pacific. It operates in two segments, Proprietary Products and Contract Manufactured Products.
Get daily news and reviews for West Pharmaceutical Services – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for West Pharmaceutical Services and related companies with MarketBeat.com’s free daily email newsletter.